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ABSTRACT 
Objective: The present investigation demonstrates a simple, sensitive and accurate high pressure liquid chromatographic (HPLC) method for the 
determination of alvimopan (AMP) in rat plasma.  
Methods: The chromatographic separation was achieved within 10 min by using acetonitrile: potassium dihydrogen phosphate buffer pH 3.0 
adjusted with orthophosphoric acid (50:50) as mobile phase on Altima Grace Smart C-18 column (5μ; 250 × 4.6 mm) at a flow rate of 1.0 ml/min 
with injection volume 50 µl. The drug was extracted from plasma by liquid-liquid extraction using a mixture of methanol: acetonitrile (50:50) as a 
solvent. The retention times of drug and internal standard were found to be 5.17 and 6.74 min, respectively. This method was validated as per the 
United States Food and Drug Administration (US-FDA) guidelines.  
Results: The results of the validation parameters were found to be within the acceptance limits. The method was linear in the concentration range 
from 5-1000 ng/ml (r2= 0.9998), and the extraction recovery was found to be 78.71±3.86% for AMP. The lower limit of quantification was found to 
be 5ng/ml, and the stability of recovered samples at different conditions was found to be more than 95%.  
Conclusion: The developed method possess good selectivity, specificity, there was no interference found in the plasma blanks at retention times of 
AMP and Internal Standard (IS). We found a good correlation between the peak area and concentration of the drug under prescribed conditions. 
Furthermore, the method can also be used to estimate the pharmacokinetic parameters of AMP. 
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Narcotic medicines that are often used to reduce the pain caused by 
gastrointestinal surgery. However, these medicines can cause a variety 
of side effects, such as nausea, vomiting, constipation and stomach 
pain, which are further leads to delay recovery in patients undergoing 
gastrointestinal surgery. Therefore, medicines that are required to 
prevent the above-mentioned side effects without diminishing the 
pain-relieving effect of narcotic medicines. Alvimopan (AMP) 
(Entereg), the only drug approved by the Food and Drug 
Administration (FDA) for the treatment of postoperative ileus [1, 2]. 
This drug behaves as a peripherally acting μ-opioid antagonist. Since 
the AMP has limited ability to cross the blood-brain barrier, many of 
the undesirable side-effects of the narcotic medicines are minimized 
without affecting analgesia or precipitating withdrawal [3, 4]. In order 
to comprehend the antagonist effect of AMP further, it is imperative to 
determine the pharmacokinetic parameters through estimation of the 
AMP in plasma using simple estimation methods. 
Several liquid chromatography-tandem mass spectrometric (LC-
MS/MS) assay methods have been employed for the determination of 
various drugs in the form of single and combined dosage forms [6-9]. 
In addition, estimation of AMP in plasma and pharmaceutical 
formulation has also been carried out using LC-MS/MS method. In 
general, this method is highly sensitive to separate and identify a 
multitude of compounds in low concentration in a complex mixture 
with little assay optimization [10, 11]. However, this method has a 
variety disadvantages. Specifically, it requires an experienced 
technician, not portable, expensive and has only moderate throughput. 
Therefore, it is important to develop a method, which is simple and 
inexpensive for the estimation of AMP in plasma for routine analysis. 
The present contribution provides a simple and regular estimation 
method for determination of AMP in rat plasma using high-pressure 
liquid chromatography (HPLC). [fig. 1] gives the molecular structure 
of AMP. As the above-mentioned, AMP is the only narcotic 
antagonist approved by the FDA for the treatment of postoperative 
surgery of gastro intestine. In order to estimate the pharmacokinetic 
parameters, we made an attempt to determine the AMP in the rat 
plasma using routine HPLC method. 
 
 




MATERIALS AND METHODS 
Chemicals and standards 
Alvimopan (AMP) procured from Aurobindo Pharma (Hyderabad, 
India), aceclofenac (ACF) purchased from S. L. drugs (Hyderabad, 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 10, Issue 10, 2018 
Habibuddin et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 10, 124-129 
 
125 
India). Purified water is prepared using a Millipore direct-Q 3 water 
purification system. Acetonitrile and methanol of HPLC grade, 
potassium dihydrogen phosphate, and orthophosphoric acid were 
purchased from Merck Ltd. (Mumbai, India). 
Preparation of standard solutions 
Preparation of AMP standard stock solution: 50 mg of AMP was 
weighed accurately and dissolved in 50 ml volumetric flask and 
made up to mark with methanol. The stock solution was diluted with 
the mobile phase solution when required.  
Preparation of Internal standard stock solution: 10 mg of ACF was 
weighed accurately dissolved in 10 ml volumetric flask and made up 
to mark with methanol.  
Preparation of phosphate buffer: Accurately weighed 2.72 g of 
potassium dihydrogen orthophosphate dissolved in 1000 ml of 
HPLC grade water and pH adjusted to 3.0 with orthophosphoric acid 
and sonicated.  
Sample preparation 
A 0.25 ml aliquot of plasma sample was spiked with 25 µl of drug (AMP) 
and 25 µl of IS, vertexes for 5 min. Added the 2 ml of a mixture of 
methanol: acetonitrile (50:50), vertexed for 5 min and the mixture was 
centrifuged for 15 min at 5000 rpm at 20°C. The supernatant liquid was 
separated and evaporated under nitrogen gas at 45°C. It reconstituted 
the residue with 0.5 ml of mobile phase and vertexed. The sample was 
filtered through 0.45µ syringe filter, then, loaded the sample into auto-
injector vial and 50 µl of the sample injected onto HPLC system.  
Method validation 
The validation of the developed method was carried out as per US 
FDA guidelines for selectivity, linearity, sensitivity, accuracy, 
precision, recovery and stability [12, 13]. 
Selectivity 
The selectivity was studied by comparing the chromatograms of six 
different batches of plasma sample obtained from six independent 
lots of control plasma along with six extracted LOQ-QC samples. The 
method is selective if there is no interfering peak present at the 
retention time of the drug or IS.  
Linearity  
A calibration curve is the relationship between instrument response 
and known concentrations of the drug. The series of standards were 
prepared by spiking the required volume of working standard to 
0.25 ml of plasma to yields the concentrations of 5, 20, 50, 100, 200, 
400, 500 and 1000 ng/ml. Extracted the drug from plasma and 
injected the each sample into HPLC. The linearity graph was plotted 
between the peak area ratios (y-axis) of AMP to IS versus the known 
concentration (x-axis) of AMP in plasma. 
Limit of quantification 
The lower limit of quantification (LLOQ) is the lowest concentration 
giving a signal-to-noise ratio of at least 10-folds, with an accuracy of 
80–120% and precision of 20% to its nominal value. This is 
determined by analyzing 10 times of LLOQ concentration and 
calculated the accuracy and precision. 
Accuracy and precision 
Intra-and inter-day accuracy and precision for this method was 
determined at three different concentration levels on three different 
days. The accuracy and precision were expressed as percentage 
accuracy and coefficient of variation (% CV) respectively. The 
accuracy was calculated as follows.  
 
The coefficient of variation, % CV was calculated as follows 
 
The accuracy determined at each concentration level must be within 
in 15% and the precision around the mean value must not exceed 
15% except the LLOQ where it must be within 20% of the % CV.  
Recovery and matrix effect 
Recovery is the detector response obtained from an amount of the 
analyte added to and extracted from the biological matrix, compared 
to the detector response obtained for the true concentration of the 
standard. It is accessed by comparing the mean peak areas of 
extracted LQC, MQC and HQC samples to the one obtained after the 
direct injection of a solution with corresponding concentration. The 
recovery of the drug was calculated by using the following formula:  
 
Matrix effect (ME) can be expressed as the suppression or 
enhancement of ionization of analyte by the presence of matrix 
components in the biological samples; quantitatively it can be 
termed as matrix factor. The matrix effect was calculated by using 
the following formula:  
 
In this study, the peak area of AMP obtained by direct injection of 
standard solution as A, the corresponding standard solution of AMP 
spiked after extraction into plasma, injected into HPLC, the peak area of 
AMP as B, standard solutions spiked in plasma before extraction and 
followed extraction procedure and injected into HPLC, the peak area of 
AMP as C. The matrix effect and extraction recovery of the IS and AMP 
determined according to Matuszewski, B. K, et al. [14]. 
Hemolytic effect 
The hemolysis effect was investigated according to the procedure 
described by Nicola C Hughes et al. [15]. The LQC and HQC of analyte 
were spiked with plasma, and hemolysed plasma samples were 
extracted and analyzed. If there is less than 15% difference of 
analyte found in the plasma as compared to hemolysed plasma, 
indicates no hemolytic effect [15]. 
Stability 
The stability of the drug solution was determined for short-term by 
keeping at room temperature (25 °C) for 24h. Autosampler stability was 
determined by storing the samples for 22 h in the autosampler. Freeze-
Thaw stability: The plasma sample spiked with drug and kept in freeze (-
20 °C) for 24h and thawed (25 °C) for 24h. The same procedure repeated 
for two more cycles then followed the extraction procedure and 
analyzed. Wet extract samples were processed, reconstituted and kept 
on the bench at room temperature and analyzed after 24h for stability. 
Dry extract samples were processed, after evaporation, which kept on 
the bench at room temperature and analyzed after 24h to check their 
stability. Each sample injected into HPLC and concentrations obtained 
were compared with the nominal values of the QC samples.  
RESULTS AND DISCUSSION 
Method development 
Method optimization 
The chromatographic method was optimized as a mixture of 20 mmol 
potassium dihydrogen phosphate buffer (pH 3.0) and acetonitrile (50:50 
v/v) at a flow rate of 1 ml/min with detection wavelength of 261 nm by 
using Altima Grace Smart C-18 column by changing various parameters 
on trial and error basis. During the method optimization, water and 
phosphate buffer in various strengths are tried along with methanol and 
acetonitrile as organic solvent. The mobile phase composition of 50:50 
v/v acetonitrile: buffer was given good resolution, retention times of 
AMP and IS with a minimal tailing factor in acceptable range. The 
method was optimized with the mobile phase composition of 
acetonitrile and phosphate buffer 50:50 (v/v). The effect of buffer 
strength on the determination of drug was studied by different buffer 
strengths (10, 20 and 50 mmol). There were no significant changes in 
the chromatographic response and peak shape with a change in buffer 
molarity. A buffer molarity of 20 mmol was selected for further analysis.  
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After several trials, the method was optimized as a mixture of 20 
mmol potassium dihydrogen phosphate buffer (pH 3.0) and 
acetonitrile (50:50 v/v), at a flow rate of 1 ml/min, at 261 nm for 
run time 15 min. These chromatographic conditions achieved a 
satisfactory resolution, retention time and tailing for AMP. The [fig. 
2] shows that standard chromatogram of AMP along with the 
internal standard (IS). 
Two extraction methods were tried for sample preparation i.e. 
protein precipitation (PPT), liquid-liquid extraction (LLE). These 
methods were studied for their effect on matrix sensitivity and 
resolution. PPT was the least effective sample preparation 
technique, often resulting in significant matrix effects due to the 
presence of many residual matrix components. LLE provided clean 
extract and reproducible recovery of AMP and IS. So, liquid-liquid 
extraction was employed in this assay development. Several 
organic solvents like ethyl acetate, dichloromethane, acetonitrile, 
methanol, and their mixtures were tried for extraction. Finally, the 
mixture of methanol and acetonitrile (50:50) was found to be 
suitable and produced a clean chromatogram for blank plasma 
samples with the best recovery of ARM, also possesses least matrix 
effect and cost-effective. It also quickly evaporate consumes less 
time for extraction. 
  
 
Fig. 2: The chromatograms of blank plasma and plasma spiked with drug (AMP) and IS 
 
We investigated several compounds to find a suitable IS, by 
preparing standard reference solution containing alvimopan along 
with aceclofenac (ACF) and telmisartan (TEL), (which were easily 
available for us) in the above selected mobile phase. It was injected 
six times on to HPLC and observed the peak shape, response, and 
interference of these peaks with the analyte. TEL as internal 
standard produced good response but poor consistent results 
obtained with longer retention time. In another evaluation of ACF as 
internal standard produced sharp peak, no interference with 
analytes peak as well as reproducible results was obtained. So, ACF 
was employed in this study as an internal standard. Hence, ACF was 
selected as internal standard for this study.  
System suitability 
The system suitability of the method was done by working stock 
standard of individual drugs (AMP and IS) were injected HPLC to 
determine the individual retention times of drugs. Then working 
standard solution was injected five times and we considered relative 
standard deviation (RSD) for five consecutive injections ≤2, the 
resolution between two adjacent peaks ≥2 and tailing factor<2 
acceptable values [16]. Resolution (R), relative standard deviation from 
five replicate injections of working standard mixture solution, tailing 
factor (T) and retention time drug was presented in [table 1]. System 
suitability test confirmed that the chromatographic system was 
adequate for the analysis planned to be done. Then, the method was 
validated for various validation parameters according to the US FDA 
guidelines [12, 13]. 
Method validation 
Selectivity and specificity 
The developed method was found selective for both AMP and IS, as 
no interference was detected at the respective retention times. The 
chromatogram of blank extracted from plasma and chromatogram of 
plasma spiked with AMP and IS at LLOQ and 200 ng/ml are shown in 
[fig. 2]. The specificity of the present method was established by 
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checking the interference of AMP retention time with that of IS. This 
was done by injecting six replicates of matrix blank with IS. The 
interference of IS retention time caused by AMP, this was done by 
injecting 6 replicates of medium concentration of AMP. In this study, 
there was no peak interference of AMP or IS retention time [fig. 2]. 
This clearly shows the specificity and selectivity of the method. 
Carryover effect  
The carryover effect of the present method was established by using six 
injections of plasma blank and an upper limit of quantification (ULOQ) of 
AMP. These samples were analyzed alternately to check any carryover in 
the blank sample. In this study, there were no such effects observed. 
 
Table 1: System suitability parameters of AMP 
Parameters AMP IS 
Retention time (min) 5.17±0.04 6.74±0.04 
Tailing factor 1.13±0.01 1.20±0.01 
Theoretical plates 5881±101 7414±131 
Peak area 49891.1±375.8 45431±310 
Note: Values are expressed in mean±SD (n=6) 
  
Matrix effect  
The matrix effect was studied at three concentration levels (LQC, 
MQC, and HQC), there was no significance difference in peak area of 
the drug in the presence and absence of matrix ions. The matrix 
factor and matrix effect were found to be 0.99 and>96% [table 2]. 
The results of ME also found within the acceptance limits indicates 
there was no significant matrix effect for AMP found in this method. 
  
Table 2: Matrix effect (ME) on the extraction of AMP from plasma 
Standard(ng/ml) MF (Matrix factor) % RSD %ME 
LQC(15) 96.35±1.96 2.04 0.96 
MQC (250) 97.88±0.99 1.01 0.98 
HQC(750) 102.77±3.79 3.69 1.03 
Note: Values are expressed in mean±SD, Number of the sample (n=3) 
 
Recovery 
The extraction recovery was determined at three concentration 
levels (LQC, MQC, and HQC) for AMP and IS by comparing the peak 
area of AMP obtained by injecting the standard drug spiked with 
plasma followed extraction, the peak area of AMP obtained by 
injection standard drug of same concentration. The extraction 
recoveries were found to be 78.71±3.86% and 68.60±0.62% for 
AMP and IS respectively. The data represented in [table 3]. 
The hemolysis effect was studied by spiking the LQC and HQC 
with hemolysed blood. The hemolysed QC samples were 
extracted and analyzed. We could not find any hemolysis effect 
in this method. 
 
Table 3: Extraction recovery of AMP and IS from rat plasma 
Drug Standard (ng/ml) Extracted matrix standard average peak area Standard drug average Peak area % Recovery 
AMP LQC (15) 6924.33±54.3 8441±111 82.03 
MQC (250) 59061±1118.06 74177±1557.32 79.62 
HQC (750) 176561±998.43 237092±10444 74.47 
Average recovery 78.71±3.86 
ACF (IS) LQC (15) 45032.33±735.41 65674.7±391.79 68.56 
MQC (250) 45115.3±612.33 65157.7±259.43 69.24 
HQC (750) 44432±241.16 65343.7±579.23 67.99 
Average Recovery 68.60±0.62 
Values are expressed in mean±SD, n=6  
 
Linearity 
The linearity of this method was evaluated by linear regression 
analysis, using the least square method. The peak area ratio of the 
drug and internal standard was used for the quantification of AMP. 
Calibration curves were linear in the concentration range of 5-1000 
ng/ml with a correlation coefficient (r2) of 0.999 and the mean 
regression equation was: y=0.005x+0.082, Where y is the peak ratio 
and x is the plasma concentration of AMP. The linearity graph was 
shown in [fig. 3]. The linearity range of present method (5-1000 
ng/ml) was useful for the determination of AMP in rat plasma. 
Sensitivity  
The standard chromatogram of AMP at LLOQ level was presented in 
[fig. 2]. The lower limit of quantitation (LLOQ) was found to be 5 
ng/ml. The percent accuracy of LLOQ was 94.60±7.57 % and 
precision denoted by %RSD was 8.00%.  
Intra-day and inter-day precision and accuracy 
The intra-and inter-day precision and accuracy of this assay were 
determined by analyzing replicates of QC samples at three 
concentrations on 6 different days. The coefficients of variation for the 
intra-and inter-day precision were<3.03%. The intra-and inter-day 
accuracies were 98.28-102.99%. The low levels of coefficients of 
variation i.e.: 1.86%-3.03% [table 4] indicate the method is accurate and 
precise. 
Robustness  
Robustness of the method was done by changing slight variation in 
the parameters like mobile phase composition, flow rate, and 
wavelength. Present method didn’t show any significant change 
when the critical parameters were modified. The tailing factor of 
the drug was always less than 2.0 and the components were well 
separated under all the changes carried out. Considering the 
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modifications in the system suitability parameters and the 
specificity of the method, as well as carrying the experiment at 




Fig. 3: Linearity graph of Alvimopan, n=6 
 
Table 4: Intra-day and inter-day accuracy and precision of AMP in plasma 
 Standard (ng/ml) Average practical concentration Accuracy mean±SD % RSD 
Intra-day 
(n=6) 
LQC (15) 15.45±0.38 102.99±2.56 2.49 
MQC (250) 245.71±4.56 98.28±1.82 1.86 
HQC (750) 752.94±22.80 100.39±3.04 3.03 
Inter-day 
(n=9) 
LQC (15) 14.95±0.41 99.64±2.74 2.75 
MQC (250) 248.84±5.53 99.54±2.21 2.23 
HQC (750) 753.03±21.46 100.40±2.86 2.85 
Note: Values are expressed in mean±SD 
 
Ruggedness 
Ruggedness was studied along with precision and accuracy of 
batches where the effect of column change and analyst change were 
observed. The observed value for column variation and results 
obtained for precision and accuracy were within the acceptance 
criteria (i.e. there were no significance changes in the retention time, 
recovery and precision of the drug). 
Stability studies  
The stability of drug was studied at different conditions for quality 
control (QC) of samples. The samples were analyzed and compared 
with freshly analyzed QC samples, no difference was found in accuracy 
and precision. There were no documented reports in the literature 
about the stability of AMP in plasma. To find any changes in stability of 
AMP in plasma, we carried out stability studies at different conditions 
like freeze-thaw, wet extract, dry extract stability etc. In the present 
method we studied the stability of AMP in plasma for 24h, freeze-thaw 
stability after three cycles and other stability studies. These studies 
enlighten the information regarding degradation of the drug during 
the analysis and storage of plasma samples. From these results 
stability of samples represented [table 5], the accuracy of all samples 
stability was found to be>95% indicating that there was no 
degradation of the drug at different conditions. 
 
Table 5: Data of different stability studies of AMP in plasma 
Stability Standard (ng/ml) Average practical concentration Accuracy % RSD 
Freeze and thaw stability LQC (15) 14.67±0.33 97.81±2.24 2.29 
MQC (250) 251.05±0.38 100.52±0.15 0.15 
HQC (750) 747.74±27.06 99.70±3.61 3.62 
Bench Top Stability 
(Short-term stability) 
LQC (15) 14.70±0.46 97.98±3.08 3.14 
MQC (250) 249.33±1.29 99.73±0.52 0.52 
HQC (750) 756.71±12.01 100.89±1.62 1.59 
In-Injector Stability 
(Auto-sampler stability) 
LQC (15) 14.81±0.09 98.75±0.61 0.61 
MQC (250) 250.65±3.08 100.26±1.23 1.23 
HQC (750) 745.68±7.11 99.42±0.95 0.95 
Wet extract Stability LQC (15) 14.65±0.38 97.63±2.56 2.62 
MQC (250) 250.53±8.90 100.21±3.56 3.56 
HQC (750) 761.89±11.46 101.58±1.53 1.51 
Dry extract Stability 
 
LQC (15) 14.88±0.37 99.21±2.50 2.52 
MQC (250) 242.82±2.47 97.13±0.99 1.02 
HQC (750) 746.92±7.84 99.59±1.05 1.05 
Note*: Actual concentration of AMP in ng/ml. Values are expressed in mean±SD, Number of samples (n=3) 
Habibuddin et al. 




The developed method possess good selectivity, specificity, there 
was no interference found in the plasma blanks at retention times of 
AMP and IS. We found a good correlation between the peak area and 
concentration of the drug under prescribed conditions and also the 
recoveries found to be 78.71% for AMP. The observation of % RSD 
less than 5 for both intra-and inter-day measurements also indicates 
a high degree of precision. A linearity range from 5-1000 ng/ml for 
AMP, this linearity range covers all the strengths of AMP. The 
stability of AMP was found to be within the limits i.e.95.39-106.79% 
concludes that there was no degradation of AMP and also stable in 
the plasma at different study conditions. The method found to be 
highly sensitivity (5 ng/ml), good accuracy, precision and no matrix 
effect on the drug economic extraction procedure will help in further 
studies of AMP. Hence this method can be applied for quantifying the 
low levels of AMP in the biological matrix without the interference of 
plasma components for future investigation of AMP. 
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